PRTK News and Press, Paratek Pharmaceuticals Inc. From 01/30/23

Summary Today, we are putting the spotlight on small biotech concern Cidara Therapeutics for the first time in more than a year and a half. The company has an impressive set of collaboration deals with larger drug firms and its first FDA approval is on the near-term horizon. An inve...

Paratek Pharmaceuticals ( NASDAQ: PRTK ) announced Wednesday that Nuzyra, a broad-spectrum antibiotic for which the company has partnered with Zai Lab Limited ( NASDAQ: ZLAB ), has been added to National Reimbursement Drug List (NRDL) in China. The decision by the country ...

BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China’s National Healthcare Security Administration (NHSA) has added the intravenous (IV) formulation of NUZYRA® (omadacycline) to the country’s National Reimbu...

Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022 Procurement Triggered by Positive Top-Line Data from Pilot Efficacy Study of NUZYRA for the Treatment of Pulmonary Anthrax Announced in December BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Par...

BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company’s independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022. Dr. Stein was selected unani...

Paratek Pharmaceuticals ( NASDAQ: PRTK ) on Monday announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s (omadacycline) effectiveness in the treatment of pulmonary anthrax. Shares +5.3% at $1.88 in early trading session. In the...

100% Survival Rate in Anthrax-infected Rabbits Treated with Omadacycline Total Revenue Recognition to Paratek of $38.1 Million BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced positive top line data from a pilot rabbit ...

BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, go...

Paratek Pharmaceuticals, Inc. (PRTK) Q3 2022 Earnings Conference Call November 03, 2022, 16:30 ET Company Participants Sarah Higgins - VP, Finance, Controller & Principal Accounting Officer Evan Loh - CEO & Director Adam Woodrow - President & Chief Co...

Paratek Pharmaceuticals press release ( NASDAQ: PRTK ): Q3 GAAP EPS of -$0.38. Revenue of $30.2M (+23.5% Y/Y). For further details see: Paratek Pharmaceuticals GAAP EPS of -$0.38, revenue of $30.2M